Heart valve study tests safer bleeding control after TAVI

NCT ID NCT05774691

Completed Disease control Sponsor: St. Antonius Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether giving a drug called protamine to all patients after a minimally invasive heart valve replacement (TAVI) reduces bleeding complications compared to giving it only when needed. The trial involved 1000 adults with aortic valve stenosis. The goal was to see if routine protamine use lowers the risk of death or serious bleeding within 30 days after the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease aortic valve stenosis Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

Contacts and locations

Locations

A.S.Z. Aalst

Aalst, Belgium
Amsterdam University Medical Center

Amsterdam, Netherlands
Leiden University Medical Center

Leiden, South Holland, Netherlands
Maastricht UMC

Maastricht, Limburg, Netherlands
St. Antonius Hospital

Nieuwegein, Utrecht, Netherlands
University Hospitals Leuven

Leuven, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.